Endo to provide fill-finish services for Novavax COVID-19 vaccine

By The Science Advisory Board staff writers

September 25, 2020 -- Par Sterile Products has entered a nonexclusive agreement with Novavax to provide fill-finish manufacturing services at its Rochester, MI, plant for Novavax's COVID-19 vaccine candidate.

Under the agreement, Par Sterile, a subsidiary of Endo International, has begun production of the NVX-CoV2373 final drug candidate, with initial batches to be used in Novavax's phase III clinical trial in the U.S. Par Sterile will also fill-finish vaccine intended for commercial distribution in the U.S.

NVX-CoV2373 is currently in multiple phase II clinical trials to evaluate safety and immunogenicity. Interim data is expected before the end of 2020. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including $388 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

Financial and other terms of the agreement were not disclosed.

Novavax begins phase II trial of COVID-19 vaccine
Novavax has dosed the first participants in a phase II portion of an ongoing clinical trial to investigate the immunogenicity and safety of NVX-CoV2373,...
Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming...
AGC expands partnership with Novavax in U.S.
AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate...
Novavax licenses COVID-19 vaccine to Takeda in Japan
Novavax and Takeda Pharmaceutical have formed a partnership for the development, manufacturing, and commercialization in Japan of NVX-CoV2373, Novavax's...

Copyright © 2020 scienceboard.net

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter